Economic Assessment
An economic assessment checks whether a product is feasible outside the lab: who would use it, what it costs to make and what it could sell for.
A complete assessment of AnTigone, a genetically modified live biotherapeuticA medicine made of live microorganisms, here a bacterium that works inside the body. product (GMO-LBP) that lowers androgen levels locally in the gut for a systemic effectReaching and acting on the whole body, not just the gut., would include: market analysis, SWOT/PESTLEStrengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE): the outside factors that affect a project., comparator evaluationAn existing product that a new product is compared against., regulatory pathway, cost analysis, scale-upMoving from small laboratory production to large-scale manufacturing. economics, price estimation, business model, equity and accessibility, and funding and risks.
At this stage in the project, our economic assessment focuses on two parts: a comparator evaluation (where does AnTigone fit among current PMOS treatments in Sweden?) and a price analysis (what price range is realistic?).
Comparative Analysis
Current PMOS treatments in Sweden mainly manage symptoms. They include off-labelUsed for a condition other than the one the medicine is officially approved for. anti-androgensA drug that blocks or reduces the effects of androgens. and insulin sensitizersA drug that helps the body respond better to insulin. (spironolactone, metformin), combined hormonal contraceptivesPills containing both an estrogen and a progestin, a synthetic progesterone-like hormone. (Leverette, Dizmine, Yasmin, Drovelis), GLP-1 receptor agonistsDrugs that mimic the gut hormone GLP-1, which lowers appetite and blood sugar. for weight management (Wegovy, Saxenda, Mounjaro), and dietary supplements (myo-inositolA sugar-like compound sold as a dietary supplement and studied for its effects on insulin response., Probi, Nupure). Table 1 shows each comparator’s role, dose and monthly price. Prices were calculated assuming 30 days per month. An exchange rate of 11 SEK to 1 € was assumed; hover over a price to see it in Euros.
| Comparator | Role | Dose | SEK/month | Source |
|---|---|---|---|---|
| Spironolactone 25 mg tablets | Anti-androgen for hirsutismExcess dark, coarse hair growth in a male-like pattern, e.g. on the face, chest or back. and acne (off-label) (A) | 50 mg daily (2 tablets); 25–100 mg per day (B) | 58 ≈ €5 (at 11 SEK per €)(C) | (A) Teede et al., 2023 (B) Accord Healthcare B.V., 2025 (C) Apotea, n.d.-c |
| Metformin 500 mg tablets | Insulin sensitizer (off-label) (A) | 1,500 mg per day (3 tablets); maximum 2.5 g a day (B) | 78≈ €7 (at 11 SEK per €) (C) | (A) Teede et al., 2023 (B) Sandoz A/S, 2025 (C) Apotea, n.d.-a |
| Leverette (Combined pill, levonorgestrel-type) | Cycle control and androgen reduction | 1 tablet daily (A) | 34≈ €3 (at 11 SEK per €) (B) | (A) Exeltis Sverige AB, 2026 (B) Hansson, 2024 |
| Dizmine 28 (Combined pill, drospirenone-type) | Cycle control, androgen reduction with anti-androgenic progestinA synthetic progesterone-like hormone that also blocks the effects of androgens. | 1 tablet daily (A) | 41≈ €4 (at 11 SEK per €) (B) | (A) Exeltis Sverige AB, 2023 (B) Hansson, 2024 |
| Yasmin 28 (Combined pill, drospirenone-type) | Cycle control, androgen reduction with anti-androgenic progestin | 1 tablet daily (A) | 81≈ €7 (at 11 SEK per €) (B) | (A) Bayer, 2023 (B) Hansson, 2024 |
Drovelis (Combined pill, estetrol-based) | Cycle control, androgen reduction with anti-androgenic progestin | 1 tablet daily (A) | 135≈ €12 (at 11 SEK per €) (B) | (A) Gedeon Richter, 2026 (B) Hansson, 2024 |
Wegovy (semaglutide) | Weight management in PMOS with obesity (off-label for PMOS) | 2.4 mg once per week (maintenance), subcutaneousUnder the skin. injection (A) | 2,700 ≈ €245 (at 11 SEK per €)(B) | |
Mounjaro (tirzepatide) | Weight management in PMOS with obesity (off-label for PMOS) | 15 mg once per week (highest maintenance dose; the others are 5 or 10 mg), subcutaneous injection (A) | 5,200≈ €473 (at 11 SEK per €) (B) | |
Saxenda (liraglutide) | Weight management in PMOS with obesity (off-label for PMOS) | Up to 3.0 mg once per day (maintenance and maximum dose), subcutaneous injection (A) | 2,600≈ €236 (at 11 SEK per €) (B) | |
Myo-inositol supplement | Over-the-counterSold without a prescription. insulin resistance supplement (A) | 2 g per day; No guideline dose specified (B) | 56 ≈ €5 (at 11 SEK per €)(C) | |
Probi Mjölksyrabakterier Original (general probiotic) | Over-the-counter, not PMOS-specific | 1 capsule per day (10 billion CFUColony-forming units: a count of live bacteria able to multiply.) (A) | 86≈ €8 (at 11 SEK per €) (B) | (A) Apotea, n.d.-b (B) Apotea, n.d.-b |
Metformin, spironolactone and the contraceptive pills cost SEK 34 to 135 per month. Weight-management drugs cost SEK 2,600 to 5,200 per month without subsidyWithout the state paying part of the cost.. AnTigone would act locally in the gut and lower testosterone throughout the body.
In order to compete, we suggest a target price of SEK 300 to 1,000 per month as it is greater than that of generic drugsCopies of a brand-name medicine sold after its patent expires, usually much cheaper. and over-the-counter supplements but below weight-management drugs. This is a target range, not a calculated price, because production and regulatory costs are still unknown.
Price Analysis
We classify our product as a live biotherapeutic product (LBP) and compare four product categories (conventional probiotics, GMO probiotics, LBPs and GMO-LBPs), because no comparable PMOS product exists.
Product Classification
The product would be an oral capsule with live, genetically engineered bacteria for a therapeutic purpose, so it would be developed as a live biotherapeutic product (LBP). Because the bacterial strain is genetically modified, additional safety assessments and GMOGenetically modified organism.-related regulatory requirements may apply in Sweden and the EU. The final regulatory classification and applicable requirements would need to be confirmed with the relevant authorities (Committee for Medicinal Products for Human Use [CHMP], 2006; Rouanet et al., 2020).
This price analysis compares four categories: conventional probiotic supplements, GMO probiotic supplements, non-GMO-LBPNon-Genetically Modified Organism used as a Live Biotherapeutic Products, and GMO-LBPs. Swedish products are used as the primary market benchmarks. No directly comparable product exists for PMOS, so the comparison is only a rough guide.
Live, naturally occurring bacteria sold as supplements to support health.
Conventional probiotics give the baseline for what consumers in Sweden pay for live bacteria.
Their main costs are bacterial cultivation, capsule formulation, packaging, quality control and distribution (Fenster et al., 2019). Table 2 shows six products from retailer websites and may change due to discounts or price updates. The monthly average was SEK 133 (≈ €12) per month, with a range of SEK 50 to 289. Four of the six cost less than SEK 100.
| Product | Pack size | Pack price (SEK) | Dose | SEK/month | Sources |
|---|---|---|---|---|---|
| Probi Mjölksyrabakterier Original | 80 capsules | 229≈ €21 (at 11 SEK per €) | 1 capsule/day | 86≈ €8 (at 11 SEK per €) | Apotea, n.d.-b; Apoteket, n.d.-f |
| Apoteket Mjölksyrabakterier | 60 capsules | 119≈ €11 (at 11 SEK per €) | 1 capsule/day | 59≈ €5 (at 11 SEK per €) | Apoteket, n.d.-b |
| BioSalma Mjölksyrabakterier | 84 capsules | 139≈ €13 (at 11 SEK per €) | 1 capsule/day | 50≈ €5 (at 11 SEK per €) | Apoteket, n.d.-c |
| Probi Lactic Acid Bacteria Immune | 90 chewable tablets | 279≈ €25 (at 11 SEK per €) | 1 tablet/day | 93≈ €8 (at 11 SEK per €) | Apoteket, n.d.-e |
| Holistic Lactovitalis Pro | 30 capsules | 289≈ €26 (at 11 SEK per €) | 1 capsule/day | 289≈ €26 (at 11 SEK per €) | Apoteket, n.d.-d |
| Alflorex | 30 capsules | 219≈ €20 (at 11 SEK per €) | 1 capsule/day | 219≈ €20 (at 11 SEK per €) | Apoteket, n.d.-a |
Live, genetically modified bacteria sold as supplements for a specific function.
They show how much genetic modification adds to the price of a live bacterial product.
Genetically Modified Probiotics (GMO Probiotics) need an environmental risk assessment under EU Directive 2001/18/EC, which can lead to measures such as biocontainment (European Parliament and Council of the European Union, 2001).
There are currently no GMO probiotics sold in the European market, making a direct price comparison not possible. The closest reference is ZBiotics Sugar-to-Fiber in the US, a drink mix with genetically engineered Bacillus subtilis, which costs USD 80 (≈ €72) for a 30-day supply (ZBiotics Company, n.d.). That is about 500% more than the average Swedish probiotic (≈ €12 per month). The figure is only indicative, because it compares one US product with Swedish products under different regulations.
Live microorganisms developed as medicines to prevent, treat or cure a disease.
They show what approved bacterial medicines cost and what drives those costs.
Live biotherapeutic products (LBPs) contain live microorganisms to prevent, treat or cure a disease, and need evidence of quality, safety and efficacyHow well a treatment works under controlled conditions.. Currently, only two are FDAU.S. Food and Drug Administration approved and on the market, Rebyota and Vowst, both a microbiota-based therapeuticMedicines made from communities of gut bacteria. used to prevent recurrent Clostridioides difficileA bacterium that causes severe, recurring gut infections, often after antibiotics. infection (Table 3).
They differ from our product in composition and use.
| Product | Use | Form | Dose | USD/course | Source |
|---|---|---|---|---|---|
| Rebyota | Prevention of recurrent C. difficile infection | Rectal suspensionA liquid medicine given through the rectum., 150 mL | 1 dose | 9,338 | Drugs.com, n.d.-a |
| Vowst | Prevention of recurrent C. difficile infection | Oral capsules, 12 per pack | 4 capsules/day for 3 days | 19,231 | Drugs.com, n.d.-b |
LBPs cost far more than probiotics. Living organisms must be produced and stored under specific conditions. Strict quality control, including strain-specific identity, potency, and anaerobic bioburden assaysTests that measure how strong a product is (potency) and how many unwanted microbes it carries (bioburden), here under oxygen-free conditions. (Microbiome Therapeutics Innovation Group & Barberio, 2024). Regulatory approval, the size of the patient population and alternative treatments also affect the price.
The LBP market is growing, from an estimated USD 2.1 billion in 2025 to USD 7.8 billion by 2034 with a CAGRCompound annual growth rate: the steady yearly growth rate that would take the market from its starting size to its final size. of 15.7% (Sharma, 2026), which may mean more established regulatory pathways and lower costs over time.
LBPs whose bacteria are genetically modified to perform a specific function in the body.
They are the category AnTigone belongs to, but none is on the market, so they cannot be priced directly.
They combine both price steps we saw above:
- the extra cost of going from a conventional probiotic to a GMO probiotic (environmental risk assessment and GMO regulation), and
- the extra cost of going from a probiotic to an LBP (clinical evidence, quality control and approval as a medicine).
Engineered LBPs also need biocontainment, GMPGood Manufacturing Practice: the quality rules a medicine has to be produced under. manufacturing and attention to environmental and societal impacts (Rutter et al., 2022). The European Commission describes the extra GMO requirements for investigational medicinal productsMedicines being tested in clinical trials, before they are approved for sale. (Directorate-General for Health and Food Safety, n.d.).
As of this assessment, no GMO-LBPs have reached the market, as they are still under clinical development.
An overview of the price differences can be found in Table 4.
| Category | Price (Sweden / reference) | Source |
|---|---|---|
| Conventional probiotics | SEK 50 to 289 per month (average 133) | Table 2 |
| GMO probiotics | ≈ SEK 790 per month (ZBiotics, USD 80) | ZBiotics Company, n.d. |
| LBPs | USD 9,338 to 19,231 per treatment course | Table 3 |
| GMO-LBPs | None on the market | N/A |
Cost Estimation
AnTigone would be a GMO-LBP, so its cost structure is closer to an LBP than to a probiotic supplement. It would carry the LBP costs (clinical development, GMP manufacturing, regulatory approval) plus GMO-specific ones (environmental risk assessment, biocontainment).
Two things that could likely lower its costs:
- It uses one defined E. coli strain and not screened human stool, so no donor screeningTesting stool donors for infections and other health risks before their material is used. is needed, as with Rebyota and Vowst.
- And since PMOS is chronic, development costs can be recovered through monthly sales to a larger group of patients.
These comparisons show what drives the price but not AnTigone’s actual cost. We therefore set a preliminary target of SEK 300 to 1,000 per month based on competition. It is above generics, pills and supplements (SEK 34 to 289), which it must justify as a new non-hormonal option, and below weight-management drugs (SEK 2,600 to 5,200). It is a target, not a cost-based estimate. ZBiotics sells an engineered live bacterial product at about SEK 790 per month, which suggests the upper end is more realistic, though it is not a medicine and cannot predict AnTigone’s costs.
A more accurate estimate needs the daily bacterial dose, production costs and development costs divided over the expected patient population. That cost model is beyond this assessment.
Limitations and Outlook
We asked whether AnTigone could work outside the lab: where it fits among current PMOS treatments, and what price is realistic.
As a GMO-LBP, its costs would be closer to approved LBPs than to supplements, so we set a competition-based target of SEK 300 to 1,000 per month, above generics, pills and supplements and below weight-management drugs. Our Clinician Survey supports a competitive price: if the product were significantly more expensive and not reimbursed, 6 of 13 clinicians would recommend it only to patients who can afford it, and 4 called cost a major barrier.
The target is based on competitors’ prices, not a cost model, so it does not show what AnTigone would cost to make.
The comparisons are imperfect: the only GMO probiotic reference is one US product, the approved LBPs treat a different condition, and no GMO-LBP is on the market. We also covered only the comparator and price parts of a full economic assessment, without market size, scale-up, funding or a business model.
The conclusion is that feasibility depends largely on production and regulatory costs, which a future cost model has to determine.
References
- Accord Healthcare B.V. (2025, June 9). Spironolactone Accord, filmdragerad tablett 25 mg: Produktresumé [Summary of product characteristics]. FASS. https://fass.se/health/product/20150717000054/smpc
- Apotea. (n.d.-a). Metformin Teva B.V., filmdragerad tablett 500 mg - 100 tablett(er). Retrieved October 15, 2026, from https://www.apotea.se/metformin-teva-b-v-filmdragerad-tablett-500-mg-2
- Apotea. (n.d.-b). Probi Mjölksyrabakterier Original, 80 kapslar. Retrieved October 15, 2026, from https://www.apotea.se/probi-mjolksyrabakterier-original-80-st
- Apotea. (n.d.-c). Spironolakton Orifarm, tablett 25 mg - 100 tablett(er). Retrieved October 15, 2026, from https://www.apotea.se/spironolakton-takeda-tablett-25-mg
- Apotea. (n.d.-d). Wegovy. Retrieved October 15, 2026, from https://www.apotea.se/wegovy
- Apoteket. (n.d.-a). Alflorex Kosttillskott med bifidobakterier, 30 st. Retrieved October 15, 2026, from https://www.apoteket.se/produkt/alflorex-30-st-lada-1567860/
- Apoteket. (n.d.-b). Apoteket Mjölksyrabakterier, 60 st. Retrieved October 15, 2026, from https://www.apoteket.se/produkt/apoteket-mjolksyrabak-c-plus-selen-60-st-ask-488921/
- Apoteket. (n.d.-c). BioSalma Mjölksyrabakterier, 84 st. Retrieved October 15, 2026, from https://www.apoteket.se/produkt/biosalmamjolksyrabakterier-84-st-burk-ej-metall-1558299/
- Apoteket. (n.d.-d). Holistic Lactovitalis pro, 30 st. Retrieved October 15, 2026, from https://www.apoteket.se/produkt/holistic-lactovitalis-pro-30-st-lada-1566262/
- Apoteket. (n.d.-e). Probi Mjölksyrabakterier Immune, 90 st. Retrieved October 15, 2026, from https://www.apoteket.se/produkt/probi-mjolksyrabakterier-immun-90-st-flaska-1570657/
- Apoteket. (n.d.-f). Probi Mjölksyrabakterier Original, 80 st. Retrieved October 15, 2026, from https://www.apoteket.se/produkt/probi-original-80-st-ask-1564158/
- Bayer. (2023, November 20). Yasmin 28 (filmdragerad tablett 0,03 mg/3 mg): Fass-text [Yasmin 28 (film-coated tablet 0.03 mg/3 mg): Fass text]. FASS Vård. https://fass.se/health/product/20000922000052/fass-text
- Committee for Medicinal Products for Human Use. (2006). Guideline on environmental risk assessments for medicinal products consisting of, or containing, genetically modified organisms (GMOs) (EMEA/CHMP/BWP/473191/2006). European Medicines Agency. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-risk-assessments-medicinal-products-consisting-or-containing-genetically-modified-organisms-gmos_en.pdf
- Directorate-General for Health and Food Safety. (n.d.). Genetically modified organism (GMO) aspects for investigational medicinal products. European Commission. Retrieved October 17, 2026, from https://health.ec.europa.eu/medicinal-products/product-types/advanced-therapies/genetically-modified-organism-gmo-aspects-investigational-medicinal-products_en
- Drugs.com. (n.d.-a). Rebyota prices, coupons, copay cards & patient assistance. Retrieved October 17, 2026, from https://www.drugs.com/price-guide/rebyota
- Drugs.com. (n.d.-b). Vowst prices, coupons, copay cards & patient assistance. Retrieved October 17, 2026, from https://www.drugs.com/price-guide/vowst
- European Medicines Agency. (2025, July 31). Saxenda: EPAR – Product information [Summary of product characteristics]. https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_en.pdf
- European Medicines Agency. (2026, September 21). Mounjaro: EPAR – Product information [Summary of product characteristics]. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
- European Parliament and Council of the European Union. (2001). Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Official Journal of the European Communities, L 106, 1–39. https://eur-lex.europa.eu/eli/dir/2001/18/oj
- Exeltis Sverige AB. (2023, December 1). Dizmine 28 (filmdragerad tablett 0,03 mg/3 mg): Fass-text [Dizmine 28 (film-coated tablet 0.03 mg/3 mg): Fass text]. FASS Vård. https://fass.se/health/product/20120316000021/fass-text
- Exeltis Sverige AB. (2026, April 16). Leverette (filmdragerad tablett 150 mikrogram/30 mikrogram): Fass-text [Leverette (film-coated tablet 150 micrograms/30 micrograms): Fass text]. FASS Vård. https://fass.se/health/product/20151103000252/fass-text
- Fenster, K., Freeburg, B., Hollard, C., Wong, C., Laursen, R. R., & Ouwehand, A. C. (2019). The production and delivery of probiotics: A review of a practical approach. Microorganisms, 7(3), Article 83. https://doi.org/10.3390/microorganisms7030083
- Gedeon Richter. (2026, March 10). Drovelis (filmdragerad tablett 3 mg/14,2 mg): Fass-text [Drovelis (film-coated tablet 3 mg/14.2 mg): Fass text]. FASS Vård. https://fass.se/health/product/20200128000010/fass-text
- Hälsokosten. (n.d.). Myo-Inositol 250g [Product page]. Retrieved October 15, 2026, from https://halsokosten.se/vitaminer-mineraler/vitaminer/vitamin-b/myo-inositol-250g
- Hansson, M. (2024, February 1). Hormonella preventivmedel: Aktuella preparat och priser [Hormonal contraceptives: Current products and prices] [PDF]. Kunskapsstöd för vårdgivare. https://kunskapsstodforvardgivare.se/download/18.3fa94b2f18e5f832b60179a2/1712072125119/Sammanstallning_aktuella_preventivmedel_2024.pdf
- Microbiome Therapeutics Innovation Group, & Barberio, D. (2024). Navigating regulatory and analytical challenges in live biotherapeutic product development and manufacturing. Frontiers in Microbiomes, 3, Article 1441290. https://doi.org/10.3389/frmbi.2024.1441290
- Novo Nordisk A/S. (2026, September). Wegovy Flex Touch (injektionsvätska, lösning i förfylld injektionspenna 0,5 mg): Produktresumé [Wegovy FlexTouch (solution for injection in pre-filled pen 0.5 mg): Summary of product characteristics]. FASS Vård. https://fass.se/health/product/20240617000060/smpc
- Region Örebro län. (2025, October 23). Obesitasläkemedel: Som stöd till viktminskning och/eller motverka viktökning [Anti-obesity medications: To support weight loss and/or prevent weight gain] [PDF]. https://vardgivare.regionorebrolan.se/siteassets/media/vardriktlinjer/lakemedelscentrum/rekommenderade-lakemedel/kort-och-lathundar/obesitaslakemedel.pdf
- Rouanet, A., Bolca, S., Bru, A., Claes, I., Cvejic, H., Girgis, H., Harper, A., Lavergne, S. N., Mathys, S., Pane, M., Pot, B., Shortt, C., Alkema, W., Bezulowsky, C., Blanquet-Diot, S., Chassard, C., Claus, S. P., Hadida, B., Hemmingsen, C., . . . Cordaillat-Simmons, M. (2020). Live biotherapeutic products, a road map for safety assessment. Frontiers in Medicine, 7, Article 237. https://doi.org/10.3389/fmed.2020.00237
- Rutter, J. W., Dekker, L., Owen, K. A., & Barnes, C. P. (2022). Microbiome engineering: Engineered live biotherapeutic products for treating human disease. Frontiers in Bioengineering and Biotechnology, 10, Article 1000873. https://doi.org/10.3389/fbioe.2022.1000873
- Sandoz A/S. (2025, March 26). Metformin Sandoz (filmdragerad tablett 500 mg): Produktresumé [Metformin Sandoz (film-coated tablet 500 mg): Summary of product characteristics]. FASS Vård. https://fass.se/health/product/20070911000042/smpc
- Sharma, R. (2026, April). Live biotherapeutics market research report 2034 (Report No. HC-725621). Dataintelo. https://dataintelo.com/report/live-biotherapeutics-market
- Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. https://doi.org/10.1210/clinem/dgad463
- ZBiotics Company. (n.d.). Sugar-to-Fiber [Product page]. Retrieved October 17, 2026, from https://zbiotics.com/products/sugar-to-fiber?variant=53865150185844